Protocol H6Q-MC-S034(a) Randomized, Double-Blind, Phase 2 Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Chemonaive Patients With Stage IIIB or IV Non-Small Cell Lung Cancer

For full description, see www.clinicaltrials.gov.

Abstracts/Posters/Presentations:

• E. M. Casey, W. Harb, D. Bradford, J. Bufill, S. Nattam, J. Patel, W. Fisher, J. E. Latz, J. Wu, N. Hanna. Randomized, Double-Blind, Multicenter, Phase II Study of Pemetrexed (PEM), Carboplatin (CARBO), Bevacizumab (BEV) with Enzastaurin (ENZ) or Placebo (PBO) in Chemo-Naïve Patients with Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN06-116. Accepted to the general poster session (abstract #8035) at the ASCO annual meeting May 29-June 2, 2009, Orlando, FL

Manuscripts/Articles:

• Casey EM, Harb W, Bradford D, Bufill J, Nattam S, Patel J, Fisher W, Latz JE, Li X, Wu J, Hanna N. Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116. J Thorac Oncol. 2010 Nov;5(11):1815-20. doi: 10.1097/JTO.0b013e3181ee820c. See abstract.